NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.
- Mechanism
- Curator reviewed
With eiRNA therapeutics, the drug consists of a DNA vector which encodes the double-stranded RNA molecules. When the DNA vector is administered to a cell or organism it will cause the cell to generate multiple copies of the desired RNAi molecules inside the cell and over an extended period of time, thereby amplifying the RNAi mechanism.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
- Code names
- NUC B1000
What you can answer from here — as of March 06, 2025
Which companies are running trials of NUC B1000, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account